• Skip to main content
  • Skip to primary sidebar

JP Cornerstone

Just another Cornerstone Accelerator site

  • JP Cornerstone
  • About
    • About JP Cornerstone
    • Code of Ethics
    • Professional Practice Guidelines
    • External Privacy Notice
  • Offices
    • Stockholm
    • Helsinki
    • Oslo
    • Copenhagen
  • Services
    • Executive Search
    • Board Search
    • Leadership Consulting
    • Interim Management
    • JPC Selection
  • News
  • Contact

China Eyes Global Leadership in Rare Disease

October 16, 2019 by Cornerstone International Group Leave a Comment

 

China is accelerating a response to rare disease

In the US, a rare disease is defined as affecting 75 in every 100,000 people, in Japan the definition is 40 out of 100,000 and in the EU it is 20 out of 100,000. In China rare disease does not yet have a specific definition, but it is under study.

The 8th China Rare Disease Summit held in Shenzhen on September 21st,  2019 was a great opportunity to measure the progress made by China.   Through exchanges with public officials, academics, representatives of patient associations and industry experts, we sensed a paradigm shift.  There are three fundamental changes, that are interconnected but not yet at the same level of maturity.

 

Regulatory Reform

First, regulatory reform has been successfully implemented. There is no longer a major backlog in the drug registration process. More importantly, the National Medical Product Administration (NMPA) has created an accelerated pathway for products for urgent needs and for which foreign data could be acceptable.

Then, a list of 121 China rare diseases has been issued by the National Health Commission (NHC) in February 2019. It is far away from the total number of rare diseases, which is estimated to be in the range of 7,000. But it is a first step towards recognizing the urgent needs of Chinese patients and the deficiency of the current Chinese drug system which is not supplying these drugs.

 

Changing Attitudes to Patients

Second, the authorities are changing their attitudes towards patient groups and associations. China is a communist country and has been historically very reluctant to recognize grass-roots organizations that the Party does not control. In the case of rare diseases, patient associations are even more important as the market rule prevents the “natural development” of drugs.

There are a very limited number of patients and these diseases are unknown to most physicians. In China on average, a patient suffering from a rare disease needs to wander around in the health system for five years before finding the right diagnosis. Therefore, the authorities are no longer trying to shut down the patient groups but are recognizing them.

The event in Shenzhen was organized by one of the patient associations and the NMPA allowed them to make the opening speech, de facto recognition of the association. We all hope that formal recognition of such groups (through legal registration) will progress soon. Even more meaningful will be their joining in the NMPA‘s registration decision-making. We understand it is under consideration.

 

Funding for Rare Diseases

The third fundamental change is funding. Economic considerations are more important than for “normal” diseases. Treatments are more costly as patients’ numbers are limited and access is more difficult as only a few medical centres are able to make a correct diagnosis. As for drug policy in China, pricing and reimbursement reform is taking a long time compared to registration reform, but progress is coming.

During the event it was confirmed that the State Medical Insurance Administration (SMIA) is considering a specific fund to cover rare disease costs. The total amount could be in the range of RMB 500,000 (USD 70,000) per patient but is not yet confirmed and the future process is not yet known.

All this progress has been achieved in the last two years.  If the new paradigms are implemented to their full extent, China could significantly impact the overall course of the global pharmaceutical industry.

With 20 percent of the world population, China has the biggest pool of patients. Thus, a rare disease in China benefits from a cohort four or five times bigger than those of the EU or US. On the economic side, there is no doubt that the Authorities are willing to find better solutions in term of access than in the US.

When reforms are fully operational, China will propose volume and reasonable prices. Professor Hu Shanlian, an eminent Chinese health economist, concluded his speech by wishing one day to see Western countries use China as a reference price when listing new products at home. Today China gets products last in the product life cycle and needs to refer to international prices.

But when all the reforms are fully operational, it could be the reverse: China attracts the launch first and then the world would refer to the China price.

( Eric Bouteiller leads Cornerstone’s Life Science and Health Practice Group. This article first appeared in the global industry website pharmaboardroom.com)

 

Filed Under: Cornerstone Blog

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Recent Posts

  • Leadership Academy: In Your Corner- Emotional Intelligence: An Important Leadership Skill for 2023 and Beyond
  • The Cornerstone Eagle – December 2022 – Pause, Reflect, Learn and Take Action.
  • Making Certain Your Organization is Resilient  
  • Leadership Academy: In Your Corner- GRIT
  • Leadership Academy: In Your Corner- Uncertainty: The Times They Are A-Changin’

Recent Comments

    Archives

    • January 2023
    • December 2022
    • November 2022
    • August 2022
    • July 2022
    • June 2022
    • March 2022
    • February 2022
    • January 2022
    • December 2021
    • November 2021
    • October 2021
    • September 2021
    • August 2021
    • July 2021
    • June 2021
    • May 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • February 2018
    • February 2017
    • January 2017
    • July 2016
    • April 2016
    • March 2016
    • February 2016
    • October 2015
    • April 2015
    • March 2015
    • October 2014
    • June 2014
    • April 2014
    • March 2014
    • February 2014
    • December 2013
    • August 2013
    • May 2013
    • April 2013
    • October 2012
    • September 2012
    • August 2012
    • May 2012
    • March 2012
    • January 2012
    • December 2011
    • November 2011
    • October 2011
    • September 2011
    • July 2011
    • May 2011
    • March 2011
    • January 2011
    • December 2010
    • August 2010
    • June 2010
    • May 2010
    • April 2010
    • March 2010
    • February 2010
    • January 2010
    • December 2009
    • November 2009
    • October 2009
    • September 2009
    • August 2009
    • July 2009
    • June 2009
    • May 2009
    • April 2009
    • March 2009
    • February 2009
    • January 2009
    • December 2008
    • November 2008
    • October 2008
    • September 2008
    • August 2008
    • July 2008
    • June 2008
    • April 2008
    • March 2008
    • February 2008
    • January 2008
    • December 2007
    • September 2007
    • August 2007
    • June 2007
    • April 2007
    • December 2006
    • November 2006
    • September 2006
    • August 2006
    • July 2006
    • June 2006
    • March 2006
    • February 2006
    • January 2006
    • November 2005
    • October 2005
    • September 2005
    • August 2005
    • July 2005
    • June 2005
    • May 2005
    • April 2005
    • March 2005
    • February 2005
    • January 2005
    • December 2004
    • November 2004
    • October 2004
    • September 2004
    • August 2004
    • July 2004
    • June 2004
    • May 2004
    • April 2004
    • March 2004
    • February 2004
    • January 2004
    • December 2003
    • November 2003
    • October 2003
    • September 2003
    • August 2003
    • July 2003
    • June 2003
    • May 2003
    • April 2003
    • March 2003
    • February 2003
    • January 2003
    • December 2002
    • November 2002

    Categories

    • Cornerstone Blog
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Copyright © 2023 · JP Cornerstone · Sitemap

    Website Development by LimeCuda